Home / Business / Healthcare & Pharmaceutical Tools: Save | Print | E-mail | Most Read | Comment
Jiangsu Hengrui gets US FDA nod for diabetes drug trials
Adjust font size:  ZoomIn ZoomOut

Chinese drugmaker Jiangsu Hengrui Medicine has got approval from the US Food and Drug Administration to conduct Phase 1 clinical trials for its drug to treat Type II diabetes.

The announcement, made on Thursday, boosted investor confidence in the company and its shares surged nearly 7 percent in the past two days. Once the drug completes the three clinical trials, it can be sold in the US markets and would be revenue accretive immediately.

Hengrui Medicine is the third Chinese drug company to get US FDA nod for clinical trials. The other two are Chinese herbal medicine companies, but until now, no made-in-China drugs have got approval for sales in the US markets.

Under US FDA regulations, the new drug has to undergo three phases of clinical trials that usually last for four to five years, before it can reach the marketplace.

Hengrui Medicine has applied for Patent Cooperation Treaty for its diabetes drug. The company has not applied to the State Food and Drug Administration for conducting any clinical trials in China and the drug is still unavailable in the mainland.

"Despite the risks and high costs, the announcement is positive from a mid-term perspective, as the clinical experiment will strengthen the company's research and development capability and help boost market confidence," said Cai Jianjun, drug analyst, Guodu Securities.

Tasly Group's Cardiotonic Pill and Kanion Pharmaceutical's Guizhi Fuling Capsule, are still undergoing clinical trials.

Clinical trials are expensive processes involving huge spends for companies. The expenditures could in some cases exceed $1 billion, said Cai.

Hengrui Medicine shares rose nearly 7 percent in last two days and closed at 38.19 yuan on Friday, following the announcement.

The global diabetes drug market is huge and has been rising rapidly. The number of diabetics worldwide is around 247 million, and the figure about China is 50 million. In 2008, sales of global diabetes drugs reached $24 billion. The market size in China is estimated to be around 7 billion yuan and set to rise 20 to 30 percent annually.

German drug firm Merck, which got approval for its diabetes drug to be sold in US markets in 2006, has since seen its sales grow nearly 109 percent to $1.4 billion in 2008, said Cai.

Dai Hongbin, secretary of the board from Hengrui Medicine, said diabetes drugs will be the new focus for the company.

(China Daily August 22, 2009)

Tools: Save | Print | E-mail | Most Read Bookmark and Share
Comment
Pet Name
Anonymous
China Archives
Related >>
June 7 Tokyo 2nd China-Japan High-Level Economic Dialogu

June 30 Shanghai 2009 Automotive Engine Technology Seminar

September 8-12 Xiamen China Int'l Fair for Investment and Trade
- Output of Major Industrial Products
- Investment by Various Sectors
- Foreign Direct Investment by Country or Region
- National Price Index
- Value of Major Commodity Import
- Money Supply
- Exchange Rate and Foreign Exchange Reserve
- What does the China-Pakistan Free Trade Agreement cover?
- How to Set up a Foreign Capital Enterprise in China?
- How Does the VAT Works in China?
- How Much RMB or Foreign Currency Can Be Physically Carried Out of or Into China?
- What Is the Electrical Fitting in China?
主站蜘蛛池模板: 日本三区四区免费高清不卡| 亚洲精品无码mv在线观看网站| 成人禁在线观看| 在线成人播放毛片| 三级理论中文字幕在线播放| 日本簧片在线观看| 亚洲人色大成年网站在线观看| 热re久久精品国产99热| 午夜亚洲国产理论秋霞| 色婷婷免费视频| 国产午夜视频在线观看第四页| caopon国产在线视频| 国产精欧美一区二区三区| a级国产乱理伦片在线观| 成人18xxxx网站| 中文字幕黄色片| 日本伊人精品一区二区三区| 久人人爽人人爽人人片AV| 欧美亚洲国产一区二区三区| 亚洲欧美一二三区| 污视频免费网站| 亚洲黄色网址大全| 玉蒲团之偷情宝鉴电影| 免费看www视频| 精品久久久久国产免费| 又黄又骚的网站| 美女黄网站人色视频免费国产| 国产乱弄免费视频| 青草视频免费看| 国产卡一卡二卡三卡四| 黄色三级三级免费看| 国产成人综合美国十次| 黄色免费网站网址| 国产欧美一区二区三区免费| 五月天久久婷婷| 国产精品19禁在线观看2021| 你懂的在线视频| 国产精品一区二区久久| jizzjizz护士| 国产片免费福利片永久| 欧美另类xxx|